Introduction to monoclonal antibodies

Cancer Immunity

Volumn 12, Issue , 2012, Pages

  Mach, Jean Pierre ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Cancer immunotherapy enhancement; Monoclonal anti cancer antibodies; Radiolabeled antibodies

Indexed keywords

BEVACIZUMAB; BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CD20 ANTIBODY; CETUXIMAB; EPITOPE; GANGLIOSIDE ANTIBODY; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 806; MONOCLONAL ANTIBODY A33; NEUROPILIN 1; PERTUZUMAB; RITUXIMAB; T LYMPHOCYTE RECEPTOR; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; BREAST CANCER; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLORECTAL CARCINOMA; ENZYME SPECIFICITY; GLIOMA; GLYCOSYLATION; HUMAN; IMMUNOMODULATION; IMMUNOSCINTIGRAPHY; LUNG NON SMALL CELL CANCER; LYMPHOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OLIGOMERIZATION; PANCREAS CARCINOMA; PROTEIN DATABASE; PROTEIN PURIFICATION; RADIOACTIVITY; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

EID: 84862243884     PISSN: 14249634     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Sci-ence 1991; 254: 1643-1647. (PMID: 1840703)
2. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autol-ogous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995; 182: 689-698. (PMID: 7544395)
3. Knuth A, Danowski B, Oettgen HF, Old LJ. T-cell-mediated cyto-toxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci U S A 1984; 81: 3511-3515. (PMID: 6610177)
4. Chen YT, Scanlan MJ, Sahin U, Türeci Ö, Gure AO, Tsang S, Wil-liamson B, Stockert E, Pfreundschuh M, Old LJ. A testicular anti-gen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997; 94: 1914-1918. (PMID: 9050879)
5. Old LJ. Cancer/testis (CT) antigens-a new link between gameto-genesis and cancer. Cancer Immun 2001; 1: 1. (PMID: 12747762)
6. Sahin U, Türeci Ö, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995; 92: 11810-11813. (PMID: 8524854)
7. Lee SY, Obata Y, Yoshida M, Stockert E, Williamson B, Jungbluth AA, Chen YT, Old LJ, Scanlan MJ. Immunomic analysis of human sarcoma. Proc Natl Acad Sci U S A 2003; 100: 2651-2656. (PMID: 12601173)
8. Mach JP, Carrel S, Merenda C, Sordat B, Cerottini JC. In vivo local-isation of radiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice. Nature 1974; 248: 704-706. (PMID: 4833275)
9. Goldenberg DM, DeLand F, Kim E, Bennett S, Primus FJ, van Nagell JR Jr, Estes N, DeSimone P, Rayburn P. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and local-ization of diverse cancers by external photoscanning. N Engl J Med 1978; 298: 1384-1386. (PMID: 349387)
10. Mach JP, Carrel S, Forni M, Ritschard J, Donath A, Alberto P. Tumor localization of radiolabeled antibodies against carcinoem-bryonic antigen in patients with carcinoma: a critical evaluation. N Engl J Med 1980; 303: 5-10. (PMID: 7189578)
11. Accolla RS, Carrel S, Mach JP. Monoclonal antibodies specific for carcinoembryonic antigen and produced by two hybrid cell lines. Proc Natl Acad Sci U S A 1980; 77: 563-566. (PMID: 6153797)
12. Mach J-P, Buchegger F, Forni M, Ritschard J, Berche C, Lumbroso J-D, Schreyer M, Girardet C, Accolla RS, Carrel S. Use of radiola-beled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy. Immunol Today 1981; 2: 239-249. (PMID: not available)
13. Delaloye B, Bischof-Delaloye A, Buchegger F, von Fliedner V, Grob JP, Volant JC, Pettavel J, Mach JP. Detection of colorectal carci-noma by emission-computerized tomography after injection of 123I-labeled Fab or F(ab')2 fragments from monoclonal anti-carci-noembryonic antigen antibodies. J Clin Invest 1986; 77: 301-311. (PMID: 3484753)
14. Halpern SE, Haindl W, Beauregard J, Hagan P, Clutter M, Amox D, Merchant B, Unger M, Mongovi C, Bartholomew R. Scintigraphy with In-111-labeled monoclonal antitumor antibodies: kinetics, biodistribution, and tumor detection. Radiology 1988; 168: 529-536. (PMID: 3393677)
15. Folli S, Wagnieres G, Pelegrin A, Calmes JM, Braichotte D, Bucheg-ger F, Chalandon Y, Hardman N, Heusser C, Givel JC, Chapuis G, Chatelain A, van den Bergh H, Mach JP. Immunophotodiagnosis of colon carcinomas in patients injected with fluoresceinated chimeric antibodies against carcinoembryonic antigen. Proc Natl Acad Sci U S A 1992; 89: 7973-7977. (PMID: 1518823)
16. Mach JP. Targeting of monoclonal antibodies for imaging and potential for therapy. Encyclopedia of Life Sciences 2002; London: Nature Publishing Group; 1-13.
17. Miller RA, Levy R. Response of cutaneous T cell lymphoma to ther-apy with hybridoma monoclonal antibody. Lancet 1981; 2: 226-230. (PMID: 6114284)
18. Hatzubai A, Maloney DG, Levy R. The use of a monoclonal anti-idiotype antibody to study the biology of a human B cell lymphoma. J Immunol 1981; 126: 2397-2402. (PMID: 6785351)
19. Mach JP, Chatal JF, Lumbroso JD, Buchegger F, Forni M, Ritschard J, Berche C, Douillard JY, Carrel S, Herlyn M, Steplewski Z, Koprowski H. Tumor localization in patients by radiolabeled monoclonal antibodies against colon carcinoma. Cancer Res 1983; 43: 5593-5600. (PMID: 6616486)
20. Sears HF, Herlyn D, Steplewski Z, Koprowski H. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 1985; 45: 5910-5913. (PMID: 4053061)
21. Riethmüller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Pichlmayr H, Schmiegel W, Buggisch P, Hoffken K, Hirche H, Pichimayr R, Buggisch P, Witte J, German Cancer Aid 17-1A Study Group. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 1994; 343: 1177-1183. (PMID: 7909866)
22. Larson SM, Carrasquillo JA, Krohn KA, Brown JP, McGuffin RW, Ferens JM, Graham MM, Hill LD, Beaumier PL, Hellström KE, Hellström I. Localization of 131I-labeled p97-specific Fab frag-ments in human melanoma as a basis for radiotherapy. J Clin Invest 1983; 72: 2101-2114. (PMID: 6196380)
23. Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, Ger-main JS, Richards EC, Larson SM, Oettgen HF. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1994; 12: 1561-1571. (PMID: 8040668)
24. Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, Germain JS, Richards EC, Larson SM, Old LJ. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1996; 14: 1787-1797. (PMID: 8656247)
25. Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA, Humm JL, Zan-zonico P, Smith-Jones PM, Divgi CR, Pryma DA, Ruan S, Kemeny NE, Fong Y, Wong D, Jaggi JS, Scheinberg DA, Gonen M, Panageas KS, Ritter G, Jungbluth AA, Old LJ, Larson SM. (124)I-huA33 anti-body PET of colorectal cancer. J Nucl Med 2011; 52: 1173-1180. (PMID: 21764796)
26. Scott AM, Lee FT, Hopkins W, Cebon JS, Wheatley JM, Liu Z, Smyth FE, Murone C, Sturrock S, MacGregor D, Hanai N, Inoue K, Yamasaki M, Brechbiel MW, Davis ID, Murphy R, Hannah A, Lim-Joon M, Chan T, Chong G, Ritter G, Hoffman EW, Burgess AW, Old LJ. Specific targeting, biodistribution, and lack of immunoge-nicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial. J Clin Oncol 2001; 19: 3976-3987. (PMID: 11579119)
27. Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, Larson SM, Warnaar SO, Fleuren GJ. Antibody local-ization in human renal cell carcinoma: a phase I study of monoclo-nal antibody G250. J Clin Oncol 1993; 11: 738-750. (PMID: 8478666)
28. Divgi CR, Bander NH, Scott AM, O'Donoghue JA, Sgouros G, Welt S, Finn RD, Morrissey F, Capitelli P, Williams JM, Deland D, Nakhre A, Oosterwijk E, Gulec S, Graham MC, Larson SM, Old LJ. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998; 4: 2729-2739. (PMID: 9829736)
29. Goldenberg DM, Gaffar SA, Bennett SJ, Beach JL. Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res 1981; 41: 4354-4360. (PMID: 7306964)
30. Buchegger F, Pfister C, Fournier K, Prevel F, Schreyer M, Carrel S, Mach JP. Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments. J Clin Invest 1989; 83: 1449-1456. (PMID: 2708519)
31. Tschmelitsch J, Barendswaard E, Williams C Jr, Yao TJ, Cohen AM, Old LJ, Welt S. Enhanced antitumor activity of combination radio-immunotherapy (131I-labeled monoclonal antibody A33) with che-motherapy (fluorouracil). Cancer Res 1997; 57: 2181-2186. (PMID: 9187118)
32. Ychou M, Azria D, Menkarios C, Faurous P, Quenet F, Saint-Aubert B, Rouanet P, Pelegrin M, Bascoul-Mollevi C, Guerreau D, Sacca-vini JC, Mach JP, Artus JC, Pelegrin A. Adjuvant radioimmuno-therapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer. Clin Cancer Res 2008; 14: 3487-3493. (PMID: 18519781)
33. Pouget JP, Navarro-Teulon I, Bardies M, Chouin N, Cartron G, Pelegrin A, Azria D. Clinical radioimmunotherapy-the role of radiobiology. Nat Rev Clin Oncol 2011; 8: 720-734. (PMID: 22064461)
34. Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conju-gate. J Nucl Med 1989; 30: 1358-1366. (PMID: 2787847)
35. Chatal JF, Campion L, Kraeber-Bodere F, Bardet S, Vuillez JP, Charbonnel B, Rohmer V, Chang CH, Sharkey RM, Goldenberg DM, Barbet J. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembry-onic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006; 24: 1705-1711. (PMID: 16549819)
36. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B, Matthews DC, Fisher LD, Bernstein ID. Radiolabeled-antibody therapy of B-cell lym-phoma with autologous bone marrow support. N Engl J Med 1993; 329: 1219-1224. (PMID: 7692295)
37. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanoui-lides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmuno-therapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodg-kin's lymphoma. J Clin Oncol 2002; 20: 2453-2463. (PMID: 12011122)
38. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD, Wahl RL. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14: 1974-1981. (PMID: 8683227)
39. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-3274. (PMID: 9336364)
40. Buchegger F, Press OW. Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lym-phoma. EJNMMI Res 2011; 1: 7. (PMID: 22214546)
41. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792. (PMID: 11248153)
42. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combi-nation with cisplatin. J Clin Oncol 2000; 18: 904-914. (PMID: 10673534)
43. Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee WK, Scott AM, Johns TG. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 2005; 11: 6390-6399. (PMID: 16144944)
44. Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS, Sela M, Yarden Y. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immuno-therapy. Proc Natl Acad Sci U S A 2005; 102: 1915-1920. (PMID: 15684082)
45. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locallyadvanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32. (PMID: 22153890)
46. Larbouret C, Robert B, Navarro-Teulon I, Thezenas S, Ladjemi MZ, Morisseau S, Campigna E, Bibeau F, Mach JP, Pelegrin A, Azria D. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res 2007; 13: 3356-3362. (PMID: 17545543)
47. Larbouret C, Robert B, Bascoul-Mollevi C, Penault-Llorca F, Ho-Pun-Cheung A, Morisseau S, Navarro-Teulon I, Mach JP, Pelegrin A, Azria D. Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xeno-grafts. Ann Oncol 2010; 21: 98-103. (PMID: 19889608)
48. Larbouret C, Gaborit N, Chardes T, Coelho M, Campigna E, Bas-coul-Mollevi C, Mach JP, Azria D, Robert B, Pelegrin A. In pancre-atic carcinoma, dual EGFR/HER2 targeting with cetuximab/ trastuzumab is more effective than treatment with trastuzumab/ erlotinib or lapatinib alone: implication of receptors' down-regula-tion and dimers' disruption. Neoplasia 2012; 14: 121-130. (PMID: 22431920)
49. Kushner BH, Kramer K, Modak S, Cheung NK. Successful multi-fold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study. J Clin Oncol 2011; 29: 1168-1174. (PMID: 21343563)
50. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc recep-tors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6: 443-446. (PMID: 10742152)
51. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colom-bat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgam-maRIIIa gene. Blood 2002; 99: 754-758. (PMID: 11806974)
52. Goodman GE, Hellström I, Yelton DE, Murray JL, O'Hara S, Meaker E, Zeigler L, Palazollo P, Nicaise C, Usakewicz J, Hellström KE. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer. Can-cer Immunol Immunother 1993; 36: 267-273. (PMID: 8382560)
53. Folli S, Pelegrin A, Chalandon Y, Yao X, Buchegger F, Lienard D, Lejeune F, Mach JP. Tumor-necrosis factor can enhance radio-anti-body uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 1993; 53: 829-836. (PMID: 8449608)
54. Niesner U, Halin C, Lozzi L, Gunthert M, Neri P, Wunderli-Allens-pach H, Zardi L, Neri D. Quantitation of the tumor-targeting prop-erties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug Chem 2002; 13: 729-736. (PMID: 12121127)
55. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, Ruoslahti E. Coadministration of a tumor-pene-trating peptide enhances the efficacy of cancer drugs. Science 2010; 328: 1031-1035. (PMID: 20378772)
56. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinote-can, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342. (PMID: 15175435)
57. Goel S, Wong AH, Jain RK. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med 2012; 2: a006486. (PMID: 22393532)
58. Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Post-mus PE, Verheul HM, Serne EH, Lammertsma AA, Smit EF. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Can-cer Cell 2012; 21: 82-91. (PMID: 22264790)
59. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276: 6591-6604. (PMID: 11096108)
60. Gasdaska JR, Sherwood S, Regan JT, Dickey LF. An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab. Mol Immunol 2012; 50: 134-141. (PMID: 22305040)
61. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M. Riethmüller G, Rein-hardt C, Baeuerle PA, Kufer P. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974-977. (PMID: 18703743)
62. Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature 1985; 314: 628-631. (PMID: 2859527)
63. Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 1985; 316: 354-356. (PMID: 3160953)
64. Barr IG, Miescher S, von Fliedner V, Buchegger F, Barras C, Lanza-vecchia A, Mach JP, Carrel S. In vivo localization of a bispecific antibody which targets human T lymphocytes to lyse human colon cancer cells. Int J Cancer 1989; 43: 501-507. (PMID: 2647641)
65. Bolhuis RL, Lamers CH, Goey SH, Eggermont AM, Trimbos JB, Stoter G, Lanzavecchia A, di Re E, Miotti S, Raspagliesi F. Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lym-phocytes: a multicenter study. Int J Cancer Suppl 1992; 7: 78-81. (PMID: 1428412)
66. Bortoletto N, Scotet E, Myamoto Y, D'Oro U, Lanzavecchia A. Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells. Eur J Immunol 2002; 32: 3102-3107. (PMID: 12385030)
67. Schoonooghe S, Burvenich I, Vervoort L, De Vos F, Mertens N, Grooten J. PH1-derived bivalent bibodies and trivalent tribodies bind differentially to shed and tumour cell-associated MUC1. Pro-tein Eng Des Sel 2010; 23: 721-728. (PMID: 20616115)
68. Jager M, Schoberth A, Ruf P, Hess J, Hennig M, Schmalfeldt B, Wimberger P, Strohlein M, Theissen B, Heiss MM, Lindhofer H. Immunomonitoring results of a phase II/III study of malignant asci-tes patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3). Cancer Res 2012; 72: 24-32. (PMID: 22044753)
69. Robert B, Guillaume P, Luescher I, Doucey MA, Cerottini JC, Romero P, Mach JP. Redirecting anti-viral CTL against cancer cells by surface targeting of monomeric MHC class I-viral peptide conju-gated to antibody fragments. Cancer Immun 2001; 1: 2. (PMID: 12747763)
70. Ogg GS, Dunbar PR, Cerundolo V, McMichael AJ, Lemoine NR, Savage P. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes. Br J Cancer 2000; 82: 1058-1062. (PMID: 10737389)
71. Donda A, Cesson V, Mach JP, Corradin G, Primus FJ, Robert B. In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor grafts. Cancer Immun 2003; 3: 11. (PMID: 12916958)
72. Lev A, Noy R, Oved K, Novak H, Segal D, Walden P, Zehn D, Reiter Y. Tumor-specific Ab-mediated targeting of MHC-peptide com-plexes induces regression of human tumor xenografts in vivo. Proc Natl Acad Sci U S A 2004; 101: 9051-9056. (PMID: 15184663)
73. Cesson V, Stirnemann K, Robert B, Luescher I, Filleron T, Corradin G, Mach JP, Donda A. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/ viral peptide conjugates. Clin Cancer Res 2006; 12: 7422-7430. (PMID: 17189415)
74. Stirnemann K, Romero JF, Baldi L, Robert B, Cesson V, Besra GS, Zauderer M, Wurm F, Corradin G, Mach JP, Macdonald HR, Donda A. Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice. J Clin Invest 2008; 118: 994-1005. (PMID: 18259610)
75. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-1736. (PMID: 8596936)
76. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Ander-son AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207: 2187-2194. (PMID: 20819927)
77. Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czer-winski D, Colevas AD, Weng WK, Clarke MF, Carlson RW, Stock-dale FE, Mollick JA, Chen L, Levy R. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012; 122: 1066-1075. (PMID: 22326955)
78. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480: 480-489. (PMID: 22193102)
79. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723. (PMID: 20525992)
80. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jung-bluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A 2008; 105: 20410-20415. (PMID: 9074257)
81. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 1989; 86: 10024-10028. (PMID: 2513569)
82. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leuke-mia. Sci Transl Med 2011; 3: 95ra73. (PMID: 21832238)
83. Pasche N, Neri D. Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 2012; in press. (PMID: 22289353)
84. Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 2011; 17: 6389-6397. (PMID: 22003066)